Search Results
Your search for ,twO matches 12324 pages
Showing 151 - 200Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery
Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...
Previously Treated ES-SCLC: I-DXd Demonstrates High Response Rate
Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody-drug conjugate, according to data presented at the International Association for the Study of Lung Cancer...
Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options
ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...
The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma
The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when used in patients with relapsed or refractory multiple myeloma after four or more prior lines of...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
Experts Share Their Perspectives on Navigating Opioid-Induced Constipation in Oncology
Constipation, a frequent and distressing side effect of cancer treatment, remains underdiagnosed and undertreated—particularly when driven by opioids. Opioid-induced constipation is distinct from functional constipation and requires tailored approaches to assessment and management. During a...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
Zidesamtinib Demonstrates Responses in ROS1-Positive NSCLC
Treatment with the next-generation ROS1 tyrosine kinase inhibitor (TKI) zidesamtinib led to antitumor activity in patients with ROS1-positive non‒small cell lung cancer (NSCLC) who had experienced disease progression on prior TKI treatments. These findings from the phase I/II ARROS-1 trial were...
Izalontamab Brengitecan Plus Osimertinib Shows Activity in First-Line EGFR-Mutant NSCLC
The novel antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren, BL-B01D1) in combination with osimertinib induced a response in all patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and EGFR-sensitizing mutations treated with the combination in ...
Novel ADC Shows Promising Efficacy in Previously Treated EGFR-Mutated NSCLC
The first-in-class EGFR × HER3 bispecific antibody-drug conjugate izalontamab brengitecan (also referred to as iza-bren; BL-B01D1) demonstrated promising efficacy results plus a manageable safety profile in the treatment of patients with previously treated EGFR-mutated non–small cell lung cancer...
Observation Outperforms Adjuvant Crizotinib for Resected ALK-Positive NSCLC
Adjuvant treatment with the first-generation ALK inhibitor crizotinib failed to improve disease-free survival outcomes over observation for patients with surgically resected ALK-positive non–small cell lung cancer (NSCLC), according to findings from the phase III E4512 trial presented at the...
All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia
As reported in the Journal of Clinical Oncology by Platzbecker et al, the European intergroup phase III APOLLO trial showed that an all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA-ATO)–based regimen was associated with improved event-free survival vs a standard ATRA plus...
A Year of Global Progress Against Cancer—and Persistent Challenges
Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...
Inherited Variants in 16 Genes May Double the Risk of Multiple Primary Cancers
Individuals carrying a rare pathogenic variant in one of 16 cancer-associated genes were 1.9 times more likely to develop a single cancer and 2.6 times more likely to develop multiple primary cancers, according to the results of a genetic association study published in JAMA Oncology. These...
Can a Common Anti-inflammatory Drug Help to Control Progression of Clonal Hematopoiesis?
Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published by Mohammadnia et al in JACC ...
Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation
A randomized controlled trial investigating the effect of providing personalized risk information to patients and their providers about the patient’s risk for advanced colorectal neoplasia has found no difference in screening uptake with either the personalized risk messages or provider...
New Report on Breast Reconstruction Preferences Among African American Women
For African American patients undergoing mastectomy, the risk of complications and the postoperative appearance of the breast are among the important drivers of preferences about breast reconstruction, according to a new report published by Shammas et al in Plastic and Reconstructive Surgery....
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
Study Shows That After Early Breast Cancer Diagnosis, Risk of a Second Cancer Is Low
For individuals diagnosed with early breast cancer, the long-term risk of developing a second primary cancer is low—around 2% to 3% greater than the general population)—according to findings published by McGale et al in The BMJ. The researchers say this information can help reassure many breast...
Mifamurtide Plus Chemotherapy for Nonmetastatic High-Grade Osteosarcoma
In a pooled analysis of the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) trials reported in the Journal of Clinical Oncology, Palmerini et al found evidence of activity with the addition of mifamurtide to chemotherapy in patients with nonmetastatic high-grade osteosarcoma...
Lu-177 Dotatate in Progressive Metastatic Pheochromocytomas and Paragangliomas
In an interim analysis of a National Institutes of Health phase II study reported in the Journal of Clinical Oncology, Lin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) was active in progressive metastatic pheochromocytomas and paragangliomas (PPGLs). As stated by the investigators,...
Can Baseline Kidney Function Predict Chronic Kidney Disease After Cisplatin Treatment?
A population-based prognostic study published in JAMA Oncology found cisplatin treatment to be associated with a predictable decrease in the estimated glomerular filtration rate. According to Grant et al, their findings place patients with lower baseline kidney function at the highest risk for...
Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?
A network meta-analysis reported in JAMA Oncology found that among first-line systemic therapy options, immunotherapy-based combinations—particularly atezolizumab plus bevacizumab—offered the most favorable therapeutic balance between survival benefit and quality-of-life preservation in...
Unmet Social Needs Distort Trust in Cancer Information, Study Shows
Researchers have found that unmet social needs was associated with less trust in cancer information received from doctors and the health-care system, according to study findings led by the American Cancer Society and published in Psycho-Oncology. “Public trust in health authorities is so essential ...
Study Finds Weather Disasters Increase Risk for U.S. Drug Supply Chain Disruption
In 2024, Hurricane Helene triggered a nationwide shortage of the country’s intravenous (IV) fluids after damaging a facility in North Carolina. A similar IV fluid shortage was caused when Hurricane Maria hit Puerto Rico in 2017. In a recent, nationwide study led by the American Cancer Society...
Can Beta Blockers Help Halt the Progression of Triple-Negative Breast Cancer?
Researchers have identified a molecular biomarker in triple-negative breast cancers that may inform when beta blockers can play a role in “switching off” tumor progression. These findings were published by Lam et al in Science Signaling. When stress hormones are released by the body’s nervous...
Identification of FAP-Expressing Tumors With Radiotracer
In a German single-center phase II trial reported in The Lancet Oncology, Pabst et al found that use of the fibroblast activation protein α (FAP)–directed radiotracer Ga-68–FAPi-46 for positron-emission tomography-computed tomography (PET-CT) has shown promising ability to identify FAP-expressing...
Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?
Rechallenge with the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) after grade 1 interstitial lung disease (ILD) appeared to be safe in a diverse real-world population, including many patients with breast cancer, as presented during the 2025 ASCO Annual Meeting.1 The ...
Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction
Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpretation of mammograms with an uncertainty quantification. According to study findings published in...
Locoregionally Advanced Nasopharyngeal Carcinoma: Comparison of Regimens Following Induction Chemotherapy
In a Chinese phase III trial reported in JAMA Oncology, Xue et al found that sequential chemoradiotherapy (SCRT) was noninferior to induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) in terms of failure-free survival in patients with locoregionally advanced nasopharyngeal...
Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC
“Neoadjuvant treatment with osimertinib, with or without chemotherapy, should be considered when planning treatment for patients with resectable, EGFR-mutated, stage II to IIIB non–small cell lung cancer [NSCLC],” according to Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and ...
Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update
ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...
Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?
The results of a cohort study published in JAMA Network Open revealed an epidemiologic association between postmastectomy implant-based breast reconstruction for any breast tumor and both B- and T-cell non-Hodgkin lymphomas of the breast. According to Kinslow et al, this includes diffuse large...
Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma
Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2025 European Hematology Association (EHA) Congress.1 Results...
A Diagnosis of Stage IV Lung Cancer at 18 Has Tested My Faith—and Made It Stronger
The main symptom that eventually led to my diagnosis of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) started in the fall of 2009. I was just 17 and in my freshman year at college when I began experiencing a persistent cough. The coughing became so unrelenting over the next month, I...
ASH Announces 2025 Hematologists to Be Honored With Top Awards and Distinguished Lectures
The American Society of Hematology (ASH) will recognize 11 hematologists who have made significant contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, on December 6–9. Rainer Storb, MD, of Fred...
Dendrimer-Based SN38 Nanoparticle Shows Favorable Safety and Activity in Advanced Solid Tumors
In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the safety and preliminary efficacy of DEP-SN38, a polylysine-based dendrimer-nanoparticle delivery platform for the topoisomerase 1 inhibitor SN38, in patients with advanced solid tumors. SN38 is the active...
Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods
In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed. Study ...
Best of ASCO 20th Anniversary: Advancing Medicine and Patient Care, ASCO Style!
For the 20th year in a row, major advances in cancer research and practice-changing clinical trials from the 2025 ASCO Annual Meeting (ASCO25) were presented at the ASCO-licensed Best of ASCO meeting, held on July 18–19, 2025, in Beirut, Lebanon. It was indeed a great celebration and commitment to...
Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy
In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estrogen receptor–positive, HER2-negative breast cancer with high-risk disease on the basis of genomic...
John C. Byrd, MD, FASCO, Named UPMC Hillman Cancer Center Director
John C. Byrd, MD, FASCO, an internationally lauded researcher and clinical specialist in hematologic malignancies, has been appointed Director of UPMC Hillman Cancer Center, effective November 2025. In his role as Director, Dr. Byrd will be responsible for all aspects of the University of...
Personalizing First-Line Therapy in NSCLC: Plasma-Guided Adaptive Treatment Approach
In patients with newly diagnosed, PD-L1–positive, advanced non–small cell lung cancer (NSCLC) who tested negative for driver mutations, implementation of plasma-guided treatment intensification—from monotherapy with the PD-1 inhibitor pembrolizumab to platinum doublet chemotherapy plus...
Smoking Cessation in Cancer Care: Challenges and Opportunities
Based on the results of a cohort study reported in JAMA Network Open, smoking worsened both cancer symptom burden and severity. However, Rieth et al noted that oncologic surgery may present a unique teachable moment for smoking cessation, as patients appeared to be highly motivated to quit. The...
Genetic Testing May Reduce Chemotherapy Side Effects for Patients With GI Cancers
For patients with gastrointestinal (GI) cancers, chemotherapy can sometimes cause severe, even life-threatening side effects in those who carry certain genetic variants that may impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting...
Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS
Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...
RCC: Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes
Genetic testing may be the only way to differentiate between common and more rare subtypes of renal cell carcinoma (RCC) to prevent misdiagnoses, according to the results of a study published in Human Pathology. Mucinous tubular and spindle cell carcinoma (MTSCC) was found to share many...
Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years
It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...
Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings
A recent study published by Menta et al in the Journal of Drugs in Dermatology found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care. Conducted by researchers at the George Washington...
Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature
In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC). Study Details The multicenter...
